Blog | HemaCare

An independent study published by the MD Anderson Cancer Center in Houston TX cites using HemaCare PBMCs to take a closer look at the SARS-CoV-2 virus to identify which of its peptide sequences would make the most effective vaccine targets.

Early in the COVID-19 pandemic, the primary goal for scientists across the globe was to save lives by developing a safe, working vaccine as quickly as possible. To that end, they succeeded admirably; with several vaccines approved, doctors finally have a powerful way to fight back against this deadly disease.

Researchers at the University of Melbourne are studying how to boost the body’s immune system to help fight off certain cancers through a healthy microbiome.

The microbiome, the collective group or community of microorganisms that have a tight connection and relationship with the rest of our bodies, is essential for our healthy existence. The most studied microbiome is that of the intestines, and it is now known to play a crucial role in more than digestion. There is a critical balance between types of microbes (bacterial, fungi, viruses) that influences the body’s biochemistry, such as cholesterol levels, blood glucose, and even brain function.

Melanoma is the most serious form of skin cancer and more likely to grow and metastasize. It has a high response rate to checkpoint inhibitor therapy compared to other cancers; however, about 60% of patients treated do not respond well or relapse. Immune checkpoints are proteins expressed on T cells and function to ensure self-tolerance, but they are also used by tumor cells to limit anti-tumor immune function.

Scientists at antibody engineering company Xencor in Monrovia, CA have just published a research paper that cites using HemaCare sourced leukopaks in the development of their new antibody platform. 

Monoclonal antibody therapy has become central to the treatment of many different diseases, including autoimmune disorders, asthma and cancer. Yet in spite of this success, many disease targets have yet to be effectively addressed. Monoclonal antibodies have trouble binding to antigens that are weakly expressed, which results in a need for higher dosing concentrations. High treatment dosages, in turn, can lead to toxicity effects. Monoclonals are also limited in that they can only block one target at a time, leaving parallel disease pathways open that can lead to treatment resistance.

A recent study looked at how checkpoint inhibitors may impact the success of immunotherapy for cancer treatment.

Immune homeostasis is crucial for human and animal survival. The immune system is equipped with cells and factors that maintain a critical balance of signals that prevent immune dysfunction. Pathways that ensure this balance are immune checkpoints, and these are essential for the self-tolerance that prevents autoimmunity. Immune checkpoint proteins modulate T-cell responses to self-proteins and antigens, including tumor antigens. The proteins are expressed on the surface of cancer and cytotoxic T cells, and cancer cells use these to evade attack by T cells.